FNA News and Press, Paragon 28 Inc. From 11/13/23

2023-11-13 10:43:01 ET More on Paragon 28 Seeking Alpha’s Quant Rating on Paragon 28 Historical earnings data for Paragon 28 Financial information for Paragon 28 For further details see: Paragon 28 says DaCosta buys 30.5K shares in the co through i...

2023-11-11 12:32:05 ET Paragon 28, Inc. (FNA) Q3 2023 Earnings Conference Call November 7, 2023, 4:30 PM ET Company Participants Matthew Brinckman - Senior Vice President, Strategy and IR Albert DaCosta - Chairman and CEO Steve Deitsch - Chief Financial Officer ...

2023-11-07 17:02:55 ET More on Paragon 28 Seeking Alpha’s Quant Rating on Paragon 28 Historical earnings data for Paragon 28 Financial information for Paragon 28 For further details see: Paragon 28 reports Q3 results

2023-11-07 16:22:04 ET More on Paragon 28 Seeking Alpha’s Quant Rating on Paragon 28 Historical earnings data for Paragon 28 Financial information for Paragon 28 For further details see: Paragon 28 announces new $150M credit facility to replace exi...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that it has received a new $150 million credit facility from Ares Capital Corporation (“the Facility&...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2023 and reaffirmed its 2023 net revenue guidance. ...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Paragon 28 Inc. (FNA) is expected to report $-0.1 for Q3 2023

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2023 after market close on Tuesday, November 7, 2023. The company’s managem...

Paragon 28, Inc. (NYSE: FNA), announced today they have received an Investigational Device Exemption (IDE) approval from the FDA to commence a feasibility study for configurations of the SMART Total Talus™ System used in conjunction with the Paragon 28 ® APEX 3D™ Total Ankl...